Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and CRISPR Therapeutics AG

Biotech Giants' SG&A Strategies: A Decade in Review

__timestampCRISPR Therapeutics AGUnited Therapeutics Corporation
Wednesday, January 1, 20145114000381287000
Thursday, January 1, 201513403000452612000
Friday, January 1, 201631056000316800000
Sunday, January 1, 201735845000330100000
Monday, January 1, 201848294000265800000
Tuesday, January 1, 201963488000336200000
Wednesday, January 1, 202088208000423900000
Friday, January 1, 2021102802000467000000
Saturday, January 1, 2022102464000487000000
Sunday, January 1, 202376162000477100000
Monday, January 1, 202472977000
Loading chart...

In pursuit of knowledge

A Decade of SG&A: United Therapeutics vs. CRISPR Therapeutics

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, United Therapeutics Corporation and CRISPR Therapeutics AG have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics consistently maintained higher SG&A expenses, peaking at nearly 487% more than CRISPR Therapeutics in 2022. This reflects their expansive operational scale and robust market presence. Meanwhile, CRISPR Therapeutics, a pioneer in gene-editing technology, has seen a steady rise in SG&A, with a notable 20-fold increase from 2014 to 2021, indicating their aggressive growth and market penetration strategy. As the biotech sector continues to innovate, understanding these financial dynamics offers valuable insights into the strategic priorities of these industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025